Merck & Co squares up to Roche with Keytruda data in triple-...

Roche’s Tecentriq still has the market for front-line immunotherapy of triple-negative breast cancer (TNBC) to itself, but maybe not for long after Merck & Co reported good

Merck builds case for six-week Keytruda dosing as FDA starts...

FDA reviews Merck & Co's Keytruda in new 'tumour agnostic' u...

Merck & Co’s Keytruda cancer immunotherapy could be set for another indication, which could open up for use in all cancer patients whose tumours have a certain genetic biomarker.

FDA to quickly review Roche's chemo-free lung cancer regimen

Roche’s challenge to Merck & Co’s immunotherapy Keytruda in first line lung cancer has gathered momentum after the FDA agreed to a fast review of Tecentriq monotherapy, preventing the n

Trial answers the KRAS question for Keytruda in lung cancer

Roche steps up Merck challenge with first-line NSCLC approva...